Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl Sells 3,084 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,084 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the transaction, the general counsel now owns 51,712 shares of the company’s stock, valued at $2,591,288.32. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bryan Wahl also recently made the following trade(s):

• On Tuesday, March 18th, Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS traded up $0.36 during mid-day trading on Thursday, reaching $49.91. 618,361 shares of the company were exchanged, compared to its average volume of 639,768. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.92 billion, a PE ratio of -13.10 and a beta of 1.05. The company’s 50 day moving average price is $48.54 and its 200 day moving average price is $45.06.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TARS. Jefferies Financial Group boosted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Guggenheim restated a “buy” rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Buy” and an average target price of $63.67.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $105,714,000. GF Fund Management CO. LTD. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Tarsus Pharmaceuticals by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock worth $3,866,000 after purchasing an additional 10,991 shares during the last quarter. Finally, Woodline Partners LP lifted its stake in Tarsus Pharmaceuticals by 52.3% in the fourth quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock worth $6,035,000 after purchasing an additional 37,417 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.